FactEvidence 2
competes withNovo Nordisk
No public evidence summary is available.
钛媒体 · 2026-10-30 23:18
View evidence
- Media钛媒体2026-10-30 23:18View source
- Media钛媒体2026-10-23 11:26View source
Company
Lilly
Structure of Lilly
Lilly
Company
30 connections
UpstreamSupply and dependency8 of 9
ConstraintsRegulation and exposure
OwnProducts and technology
OwnershipInvestment and holdings
DownstreamCustomers1 of 2
PeersCompetition and partners
Relationship began
LillyCompany · 30 connections
Layer 1UpstreamSupply and dependency8
DownstreamCustomers1
PeersCompetition and partners6
OwnershipInvestment and holdings6
OwnProducts and technology7
ConstraintsRegulation and exposure2
Place in the network
No. 180 of 73094top 1%up 274 places this week
30 direct links
In a group of 1157 closely linked entities, around
New links this week
- operates in neuroscience research and development
- located in Indianapolis, Indiana
- acquires Merida Biosciences
- manufactures Cancer medicines
- produces EBGLYSS (lebrikizumab-lbkz)
- produces Foundayo (orforglipron)
- produces EloraTZP
- produces Zepbound (tirzepatide)
Weighted by public relations with evidence, recomputed daily.
Relations
Money between companies
Who invests in, owns, acquires or finances whom, from the relations AiSeek holds with evidence.
From Lilly
- Omvohowns
- AtaiBeckley Inc.acquires
- Curevo Inc.acquires
- Merida Biosciencesacquires
- 联合创新实验室invests in
- Adverumacquires
Lines show that a relation exists and which way it points; their thickness carries no amount. Dots only move to show the direction.
Arrows show the direction of the relationship. Filter to focus on a business area.
- Geography · Indianapolis, IndianaEvidence 1Fact95%
View evidence
- RegulatorSEC EDGAR current 8-K filings2026-10-29 19:03
Mailing Address LILLY CORPORATE CENTER DROP CODE 1094 INDIANAPOLIS IN 46285
View source
- Fact90%
- Mediar Therapeuticsagreement with →LillyFact90%
- Fact90%
- Company · AtaiBeckley Inc.Evidence 2Fact90%
View evidence
- CompanyPR Newswire news releases2026-10-29 18:45
Lilly completes acquisition of AtaiBeckley
View source - CompanyPR Newswire news releases2026-10-29 18:45
The Q3 2026 charges primarily related to the acquisitions of AtaiBeckley Inc. and Curevo Inc.
View source
- Company · Curevo Inc.Evidence 1Fact90%
View evidence
- CompanyPR Newswire news releases2026-10-29 18:45
The Q3 2026 charges primarily related to the acquisitions of AtaiBeckley Inc. and Curevo Inc.
View source
- Product · OmvohEvidence 1Fact90%
View evidence
- CompanyPR Newswire news releases2026-10-29 18:45
Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis
View source
- Product · Taltz (ixekizumab)Evidence 1Fact90%
View evidence
- CompanyPR Newswire news releases2026-10-29 18:45
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding
View source
Showing 1 to 8 of 34
Claims
Read the assertion alongside its sources. Expand a row to inspect the evidence.
FactEvidence 1
third quarter revenue24.4 billion
No public evidence summary is available.
GDELT Global Knowledge Graph · 2026-10-30 09:15
View evidence
- MediaGDELT Global Knowledge Graph2026-10-30 09:15View source
FactEvidence 1
year over year revenue increase39 %
No public evidence summary is available.
GDELT Global Knowledge Graph · 2026-10-30 09:15
View evidence
- MediaGDELT Global Knowledge Graph2026-10-30 09:15View source
FactEvidence 1
share price changemore than 6 %
No public evidence summary is available.
GDELT Global Knowledge Graph · 2026-10-30 09:15
View evidence
- MediaGDELT Global Knowledge Graph2026-10-30 09:15View source
FactEvidence 1
Claims910億至920億 美元
No public evidence summary is available.
科技新報 · 2026-10-30 08:50
View evidence
- Media科技新報2026-10-30 08:50View source
FactEvidence 1
Claims逾50萬名 患者
No public evidence summary is available.
科技新報 · 2026-10-30 08:50
View evidence
- Media科技新報2026-10-30 08:50View source
Showing 1 to 6 of 40
Market and valuation
Valuation data is available on Pro and Research.
Included in ProSuggest a page to watch
Know a page of this company that matters, such as pricing, a changelog, terms or careers? Suggest it. We read every suggestion; a page we add is watched for everyone, and we only count a change when two looks in a row agree.
Not available: Company signals · Financials · Filings · Sites · Guidance